{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=VEGF&page=7",
    "query": {
      "condition": "VEGF",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 426,
    "total_pages": 43,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=VEGF&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=VEGF&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-29T05:35:58.043Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00430781",
      "title": "Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms, Uterine Cervix",
        "Metastatic Cervical Cancer"
      ],
      "interventions": [
        {
          "name": "pazopanib (GW786034)",
          "type": "DRUG"
        },
        {
          "name": "lapatinib (GW572016)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 228,
      "start_date": "2006-11",
      "completion_date": "2011-07",
      "has_results": true,
      "last_update_posted_date": "2015-05-08",
      "last_synced_at": "2026-10-29T05:35:58.043Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Orange, California • Stanford, California + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00430781"
    },
    {
      "nct_id": "NCT02397954",
      "title": "A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Idiopathic Polypoidal Choroidal Vasculopathy"
      ],
      "interventions": [
        {
          "name": "Avacincaptad Pegol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ophthotech Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2015-03-12",
      "completion_date": "2015-10-23",
      "has_results": true,
      "last_update_posted_date": "2025-03-20",
      "last_synced_at": "2026-10-29T05:35:58.043Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02397954"
    },
    {
      "nct_id": "NCT00049322",
      "title": "Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Liver Cancer"
      ],
      "interventions": [
        {
          "name": "bevacizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2003-06",
      "completion_date": "2012-02",
      "has_results": true,
      "last_update_posted_date": "2020-09-01",
      "last_synced_at": "2026-10-29T05:35:58.043Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00049322"
    },
    {
      "nct_id": "NCT00287495",
      "title": "BAY 43-9006 (Sorafenib) to Treat Patients With Kaposi's Sarcoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Kaposi's Sarcoma",
        "HHV-8",
        "KSHV"
      ],
      "interventions": [
        {
          "name": "BAY 43-9006",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "110 Years",
        "sex": "ALL",
        "summary": "18 Years to 110 Years"
      },
      "enrollment_count": 10,
      "start_date": "2006-02-02",
      "completion_date": "2017-10-18",
      "has_results": false,
      "last_update_posted_date": "2019-12-12",
      "last_synced_at": "2026-10-29T05:35:58.043Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00287495"
    },
    {
      "nct_id": "NCT00964795",
      "title": "Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular (\"Wet\") Age-related Macular Degeneration (AMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Intravitreal Aflibercept Injection 2mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 323,
      "start_date": "2009-12",
      "completion_date": "2013-08",
      "has_results": true,
      "last_update_posted_date": "2015-03-23",
      "last_synced_at": "2026-10-29T05:35:58.043Z",
      "location_count": 115,
      "location_summary": "Birmingham (2 Locations), Alabama • Phoenix (2 Locations), Arizona • Tucson (2 Locations), Arizona + 112 more",
      "locations": [
        {
          "city": "Birmingham (2 Locations)",
          "state": "Alabama"
        },
        {
          "city": "Phoenix (2 Locations)",
          "state": "Arizona"
        },
        {
          "city": "Tucson (2 Locations)",
          "state": "Arizona"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00964795"
    },
    {
      "nct_id": "NCT01263782",
      "title": "BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Cixutumumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2011-05-17",
      "completion_date": "2017-08-15",
      "has_results": true,
      "last_update_posted_date": "2019-05-15",
      "last_synced_at": "2026-10-29T05:35:58.043Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01263782"
    },
    {
      "nct_id": "NCT02036424",
      "title": "Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "Ozurdex",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Raj K. Maturi, MD",
      "sponsor_class": "INDIV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2014-01",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2015-12-01",
      "last_synced_at": "2026-10-29T05:35:58.043Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02036424"
    },
    {
      "nct_id": "NCT00056459",
      "title": "Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Colorectal Neoplasms",
        "Colonic Neoplasms",
        "Rectal Neoplasms"
      ],
      "interventions": [
        {
          "name": "Vatalanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1168,
      "start_date": "2003-02",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2020-02-10",
      "last_synced_at": "2026-10-29T05:35:58.043Z",
      "location_count": 145,
      "location_summary": "Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 123 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00056459"
    },
    {
      "nct_id": "NCT05984927",
      "title": "NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "NG101 AAV gene therapy",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Elisigen, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "50 Years to 89 Years"
      },
      "enrollment_count": 20,
      "start_date": "2023-09-08",
      "completion_date": "2030-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-10-29T05:35:58.043Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05984927"
    },
    {
      "nct_id": "NCT05542381",
      "title": "The Role of Loteprednol in Reducing Post-Intravitreal Injection Related Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Loteprednol Etabonate Ophthalmic Gel [Lotemax]",
          "type": "DRUG"
        },
        {
          "name": "Refresh Lubricant Eye Drops [Artificial Tears]",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Virginia Polytechnic Institute and State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2022-12-22",
      "completion_date": "2025-05-01",
      "has_results": false,
      "last_update_posted_date": "2025-09-19",
      "last_synced_at": "2026-10-29T05:35:58.043Z",
      "location_count": 1,
      "location_summary": "Roanoke, Virginia",
      "locations": [
        {
          "city": "Roanoke",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05542381"
    }
  ]
}